Investor Presentation First Nine Months of 2023
81
Investor presentation
First nine months of 2023
Building upon a 40-year legacy to capture the Rare disease
strategic opportunity
A strategy anchored in Rare blood and endocrine disorders
Three strategic horizons towards 2030
Iron disorders
Rare anaemias
Haemoglobinopathies
Rare bleeding
disorders
Haemato-renal
disorders
Rare pituitary &
adrenal disorders
RBD
RED
Rare blood disorders
Rare endocrine disorders
Rare bone health
Growth disorders
Novo NordiskⓇ
Short-term
Maximise current
portfolio
Medium-term
Succeed with next-
generation launches
Long-term
Expand from core
New disease areas
via accelerated
internal and external
innovation
esperoct norditropin®
turoctocog alfa pegol
refixia®
nonacog beta pegol
(somatropin) injection
NovoSevenⓇRT
Coagulation Factor Vila
(Recombinant)
SOGROYA
somapacitan
Concizumab
& Mim8
NedosiranView entire presentation